T4b期胸段食管鳞癌同期放化疗疗效分析

doi:10.3760/cma.j.issn.1004-4221.2018.12.005

Abstract
Figure/Table
References()
Related Citation (15)
Read Tracking
Download Tracking

Download: PDF (0 KB) HTML (1 KB)
Export: BibTeX | EndNote (RIS) Supporting Info

Abstract Objective We aimed to analyze the clinical efficacy and treatment-related complications in patients with T4b esophageal squamous cell carcinoma (SCC) who received concurrent CRT,and to explore the potential prognostic factors related to survival. Methods Between 2010 and 2015,143 patients with T4b esophageal SCC treated with CRT were analyzed,including 71% patients with trachea and/or bronchus invasion and 44% patients with aorta and/or large vessel invasion. The median radiation dose was 60 Gy (range,44-68 Gy) with conventional fractionation,including 69 patients (48%) treated with three-dimensional conformal radiotherapy and 74 patients (52%) treated with intensity-modulated radiotherapy. All patients received concurrent platinum-based chemotherapy during radiotherapy. Kaplan-Meier method was used to analyze the survival,the log-rank test was used to examine group differences,and the Cox regression model was used for multivariate analysis. Results The median overall survival (OS) time for the whole cohort was 12.2 months. The 2-and 3-year OS rates were 34% and 29%,respectively. A total of 51 patients experienced ≥2 severe non-hematological complications,including 42 esophageal fistula,6 pneumonia,and 3 esophageal hemorrhage. Patients with severe complications showed significantly worse survival than those without complications (6.9 months vs.20.4 months,P<0.01).Multivariate analysis revealed that TNM stage and severe complications were independent prognostic factors for OS. Conclusions Patients with T4b esophageal SCC who received CRT showed satisfactory survival but with high risk of severe complications. Therefore,prevention and treatment of severe complications is the key to improve efficacy.

	Service

	E-mail this article
	Add to my bookshelf
	Add to citation manager
	E-mail Alert
	RSS
	Articles by authors
	Hu Yonghong
	Li Qiaoqiao
	Xi Mian
	Zhu Yujia
	Liu Hui
	Li Qun
	Liu Mengzhong

Key words： Esophageal neoplasms/chemoradiotherapy Prognosis

Received: 12 September 2018

Corresponding Authors: Liu Mengzhong,Email:liumzh@sysucc.org.cn

Cite this article:

Hu Yonghong,Li Qiaoqiao,Xi Mian et al. Survival analysis for patients with T4b squamous cell carcinoma of thoracic esophagus receiving concurrent chemoradiotherapy[J]. Chinese Journal of Radiation Oncology, 2018, 27(12): 1056-1060.

URL:

http://journal12.magtechjournal.com/Jweb_fszlx/EN/10.3760/cma.j.issn.1004-4221.2018.12.005 OR http://journal12.magtechjournal.com/Jweb_fszlx/EN/Y2018/V27/I12/1056

[1] 谭立君,肖泽芬,张红星,等.不能手术食管癌三维放疗与同期放化疗生存比较[J].中华放射肿瘤学杂志,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002.
Tan LJ,Xiao ZF,Zhang HX,et al. Survival comparison of three-dimensional radiotherapy alone with concurrent chemoradiotherapy for non-surgical esophageal carcinoma[J].Chin J Radiat Oncol,2015,24(2):106-110.DOI:10.3760/cma.j.issn.1004-4221.2015.02.002.
[2] 陈尔成,刘孟忠,胡永红,等.不能手术切除行同期放化疗的食管癌患者预后的多因素分析[J].癌症,2005,24(6):731-734.DOI:10.3969/j.issn.1000-467X.2005.06.021.
Chen EC,Liu MZ,Hu YH,et al. Multivariate prognostic analysis for patients with unresectable esophageal aarcinoma after concurrent chemoradiotherapy[J].Chin J Cancer,2005,24(6):731-734.DOI:10.3969/j.issn.1000-467X.2005.06.021.
[3] 李红云,祝淑钗,苏景伟,等.食管癌根治性放化疗长期生存影响因素分析[J].中华放射肿瘤学杂志,2016,25(11):1177-1181.DOI:10.3760/cma.j.issn.1004-4221.2016.11.007.
Li HU,Zhu SC,Su JW,et al. An analysis of the influencing factors for long-term survival in patients with esophageal carcinoma undergoing radical chemoradiotherapy[J].Chin J Radiat Oncol,2016,25(11):1177-1181.DOI:10.3760/cma.j.issn.1004-4221.2016.11.007.
[4] Edge SB,Compton CC.The American joint committee on cancer:the 7^th edition of the AJCC cancer staging manual and the future of TNM[J].Ann Surg Oncol,2010,17(6):1471-1474.DOI:10.1245/s10434-010-0985-4.
[5] 中国非手术治疗食管癌临床分期专家小组.非手术治疗食管癌的临床分期标准[J].中华放射肿瘤学杂志,2015,19(3):179-
180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.
China non-surgical treatment of esophageal cancer clinical staging group. Clinical staging criteria for non-surgical treatment of esophageal cancer[J].Chin J Radiat Oncol, 2015,19(3):179-180.DOI:10.3760/cma.j.issn.1004-4221.2010.03.001.
[6] Common terminology criteria adverse events (CTCAE) version 4.0[M].Published:2009.
[7] Tabira Y,Yasunaga M,Nakano KY,et al. All pathological T4 esophageal carcinomas should be categorized as stage ⅠV[J].Hepatogastroenterology.2002,49(45):694-698.
[8] Kaneko K1,Ito H,Konishi K,et al. Definitive chemoradiotherapy for patients with malignant stricture due to T3 or T4 squamous cell carcinoma of the oesophagus[J].Br J Cancer,2003,88(1):18-24.
[9] Rice TW,Kelsen D., Blackstone EH.et al. AJCC cancer staging manual[M].8 ed. New York;Springer,2017:185–202.
[10] Nishimura Y,Suzuki M,Nakamatsu K,et al. Prospective trial of concurrent chemoradiotherapy with protracted infusion of 5-fluorouracil and cisplatin for T4 esophageal cancer with or without fistula[J].Int J Radiat Oncol Biol Phys.2002,53(1):134-139.
[11] Ishida K,Ando N,Yamamoto Set al. Phase Ⅱ study of cisplatin and 5-fluorouracil with concurrent radiotherapy in advanced squamous cell carcinoma of the esophagus:a Japan Esophageal Oncology Group (JEOG)/Japan Clinical Oncology Group trial (JCOG9516)[J].Jpn J Clin Oncol,2004,34(10):615-619.
[12] 肖泽芬,杨宗贻,吕宁,等.放射治疗食管癌穿孔预后因素的分析[J].中华放射肿瘤学杂志,1999,6(4):218-220.
Xiao ZF,Yang ZY,Lyu N,et al. Prforation during or after rdiotherapy for eophageal carcinoma[J].Chin J Radiat Oncol,1999,6(4):218-220.
[13] 刘青松,章文成,关勇,等.食管瘘及出血危险因素分析[J].中华放射肿瘤学杂志,2016,25(11):1182-1186.DOI:10.3760/cma.j.issn.1004-4221.2016.11.008.
Liu QS,Zhang WC,Guan Y,et al. An analysis of risk factors for esophageal fistula and fatal bleeding after intensity-modulated radiotherapy for esophageal cancer[J].Chin J Radit Oncol,2016,25(11):1182-1186.DOI:10.3760/cma.j.issn.1004-4221.2016.11.008.
[14] Tsushima T,Mizusawa J,Sudo K,et al. Japan Esophageal Oncology Group of Japan Clinical Oncology Group (JCOG).Risk factors for esophageal fistula associated with chemoradiotherapy for locally advanced unresectable esophageal cancer:a supplementary analysis of JCOG0303[J].Medicine,2016,95(20):e3699.DOI:10.1097/MD.0000000000003699.
[15] 肖泽芬,林冬梅,吕宁,等.32例食管癌放射治疗后死亡的尸检分析[J].中华放射肿瘤学杂志,2001,10(2):81-83.DOI:10.3760/j.issn:1004-4221.2001.02.003.
Xiao ZF,Lin DM,Lyu N,et al. Autopsy finding in 32 cases treated by external beam radiotherapy alone for esophageal carcinoma[J].Chin J Radiat Oncol, 2001,10(2):81-83.DOI:10.3760/j.issn:1004-4221.2001.02.003.
[16] Lee GIH,Kim SJ,Jeong YJ,et al. Clinical implication of PET/MR imaging in preoperative esophageal cancer staging:comparison with PET/CT,endoscopic ultrasonography,and CT.Clinical implication of PET/MR imaging in preoperative esophageal cancer staging:comparison with PET/CT,endoscopic ultrasonography,and CT[J].J Nucl Med,2014,55(8):1242-1247.DOI:10.2967/jnumed.114.138974.
[17] Nishimura Y,Osugi H,Inoue K,et al. Bronchoscopic ultrasonography in the diagnosis of tracheobronchial invasion of esophageal cancer[J].J Ultrasound Med.2002,21(1):49-58.
[18] Besharat S,Jabbari A,Semnani S,et al. Inoperable esophageal cancer and outcome of palliative care[J].World J Gastroenterol.2008,14(23):3725-3728.
[19] Qureshi YA,Muntzer-Mughal M,Fragkos KC,et al. Acquired adult aerodigestive fistula:classification and management[J].J Gastrointest Surg.2018,25.DOI:10.1007/s11605-018-3811-0.